A5052032923- Lung Cancer Treatments and Mutations
- Hepatocellular Carcinoma Treatment and Prognosis
- Cholangiocarcinoma and Gallbladder Cancer Studies
- Cancer Genomics and Diagnostics
- Cancer Immunotherapy and Biomarkers
- Lung Cancer Diagnosis and Treatment
- PI3K/AKT/mTOR signaling in cancer
- Genetic factors in colorectal cancer
- Health Systems, Economic Evaluations, Quality of Life
- Advanced Breast Cancer Therapies
- HER2/EGFR in Cancer Research
- Science, Research, and Medicine
- Radiomics and Machine Learning in Medical Imaging
- Glioma Diagnosis and Treatment
- Cancer Mechanisms and Therapy
- Lung Cancer Research Studies
- Multiple and Secondary Primary Cancers
- Gastric Cancer Management and Outcomes
- Colorectal Cancer Treatments and Studies
Erasmus MC Cancer Institute
2023-2024
Erasmus MC
2024
Erasmus University Rotterdam
2024
Radboud University Nijmegen
2022-2023
Radboud University Medical Center
2022-2023
The Drug Rediscovery Protocol (DRUP) is a Dutch, pan-cancer, nonrandomized clinical trial that aims to investigate the efficacy and safety of targeted immunotherapies outside their registered indication in patients with advanced or metastatic cancer.
BackgroundIn 2–5% of patients with colorectal cancer (CRC), human epidermal growth factor 2 (HER2) is amplified or overexpressed. Despite prior evidence that anti-HER2 therapy confers clinical benefit (CB) in one-third these patients, it not approved for this indication Europe. In the Drug Rediscovery Protocol (DRUP), are treated off-label drugs based on their molecular profile. Here, we present results cohort 'trastuzumab/pertuzumab treatment-refractory RAS/BRAF-wild-type HER2amplified...
Abstract In the Drug Rediscovery Protocol (DRUP), patients with cancer are treated based on their tumor molecular profile approved targeted and immunotherapies outside labeled indication. Importantly, undergo a biopsy for whole‐genome sequencing (WGS) which allows WGS‐based evaluation of routine diagnostics. Notably, we observed that not all biopsies dMMR/MSI‐positive tumors as determined by diagnostics were classified microsatellite‐unstable subsequent WGS. Therefore, aimed to evaluate...
Abstract Background. MET mutations occur in 3-4% of advanced non-small cell lung cancer (aNSCLC), correlating with poor survival. Despite known sensitivity mutated (METmut) aNSCLC to c-MET-inhibition, no approved therapies existed until 2022. Methods. In the Drug Rediscovery Protocol (NCT0295234), patients an actionable molecular profile are treated off-label registered drugs. Both and untreated harboring exon 14 skipping (METex14) or other METmuts received crizotinib 250 mg BID disease...
Abstract Background The prognosis of malignant primary high-grade brain tumors, predominantly glioblastomas, is poor despite intensive multimodality treatment options. In more than 50% patients with potentially targetable mutations are present, including rearrangements, altered splicing, and/or focal amplifications epidermal growth factor receptor (EGFR) by signaling through the RAF/RAS pathway. We studied whether clinically available anti-EGFR monoclonal antibody panitumumab provides...
<p>Flowchart of the accrual and follow-up cohort. Abbreviations: NSCLC, non small cell lung cancer.</p>
<div>AbstractPurpose:<p> To provide patients with <i>MET</i>-mutated advanced non–small cell lung cancer (<i>MET</i>mut aNSCLC) access to crizotinib, further substantiate evidence of its efficacy and safety in this setting, find potential biomarkers for nonresponse.</p>Patients Methods:<p>In the Drug Rediscovery Protocol (NCT0295234), an actionable molecular profile are treated off-label registered drugs. Both untreated aNSCLC harboring...
<p>Site or type of first progression all patients that started crizotinib treatment. * Multiple sites include: bone and lymph node; bone, heart lung; lung pleura; brain bone; thyroid gland.</p>
<p>Representativeness of the participants included in current study for general population.</p>
<p>Baseline characteristics of all patients that completed at least one treatment cycle, stratified by objective response. Percentages may not total 100 due to rounding. Annotations: * Two with non-small cell lung cancer otherwise specified (no response) and patient undifferentiated (objective response). ® Missing for Abbreviations: IQR, Interquartile range; ECOG, Eastern Cooperative Oncology Group; PD-L1, Programmed death-ligand 1.</p>
<p>Type of Met alterations found by both inclusion diagnostics and WGS. Variants annotated according to the NM_000245 (MANE transcript). Abbreviations: NGS, next generation sequencing; PCR, polymerase chain reaction; WGS, whole genome sequencing.</p>
<p>Study characteristics and efficacy outcomes of trials with selective type 1b c-MET-inhibitors in MET mutated NSCLC. Abbreviations: ECOG, Eastern Cooperative Oncology Group; ORR, objective response rate; CI, confidence interval; mDoR, median duration response; mPFS, progression free survival; mOS, overall METex14, exon 14 skipping mutations; NA, not available.</p>
<p>Study characteristics and efficacy outcomes of trials with crizotinib in MET mutated NSCLC. Abbreviations: ECOG, Eastern Cooperative Oncology Group; ORR, objective response rate; CI, confidence interval; mDoR, median duration response; mPFS, progression free survival; mOS, overall METex14, exon 14 skipping mutations; METamp, amplification; METmut, METmutation; NA, not available.</p>
<p>Results of the differential expression analysis.</p>